Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China

China has nearly one fifth of global multidrug-resistant tuberculosis (MDR-TB) cases

From:
Department for International Development
Published
1 April 2015
Country:
China
Document Type:
Journal Article
Theme:
Health
Authors:
Wei, X.L, Yin, J, Zou, G.Y., Zhang, Z-T and Walley, J
Show 6 more
Harwell, J, Li, HT, Sun, Q, Li, RZ, Zhang, X-L, and Wang, L-X

Abstract

China has nearly one fifth of global multidrug-resistant tuberculosis (MDR-TB) cases, and follows the 24-month World Health Organization standardised regimens. This paper aims to assess treatment interruption among MDR-TB patients and its association with the provision of directly observed treatment

This research is supported by the Department for International Development’s COMDIS–HSD Programme which is led by the University of Leeds

Citation

X-L. Wei, J. Yin, G-Y. Zou, Z-T. Zhang, J. Walley, J. Harwell, H-T. Li, Q. Sun, R-Z. Li,L-X. Wang, X-L. Zhang.
Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China The International Journal of Tuberculosis and Lung Disease Vol 19, Number 4 (2015) pp 413-19 DOI: 10.5588/ijtld.14.0485 (Subscription or purchase of article required)

Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China

Updates to this page

Published 1 April 2015
Contents